Merck & Co Inc (Symbol: MRK) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

Behind negative returns for shares of American Express and Merck, the Dow Jones Industrial Average is declining Friday morning.

Shares of Merck & Co. Inc. MRK slumped 0.79% to $109.40 Thursday, on what proved to be an all-around rough trading session ...

Below is a chart showing FND's trailing twelve month trading history, with the $100 strike highlighted in orange: And Merck & Co Inc (Symbol: MRK) saw options trading volume of 48,833 contracts ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Deep-pocketed investors have adopted a bearish approach towards Merck & Co MRK, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Germany’s Merck KGaA has reached a deal with Chinese pharma company Jiangsu Hengrui that covers a pair of cancer drugs, including a ‘next-generation’ PARP inhibitor and an antibody-drug ...

**NM signifies a non meaningful value. A dash signifies the data is not available.